Patients with KCCQ-CSS of ≤ 80 would be a suitable target for the phase 3 trial going forward, he said. "The mitotropes are altering the utilization of energy to a more efficient form," Maron said.

Women lost more weight than men did, 12.6% at 1 year compared with 10.2%, but otherwise had similar improvements in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS).

The mean change in KCCQ-CSS from baseline to week 52 was 16.6 points with semaglutide versus 8.7 points with placebo (estimated treatment difference [ETD]: 7.8 points, 95% confidence interval [CI ...

KCCQ-CSS significantly improved in both groups; the extent of improvement was greater in those with moderate to severe symptoms vs. mild symptoms (P = .02 for interaction), according to the study.

At 52 weeks, the mean change in KCCQ-CSS was 13.7 points in the semaglutide groups and 6.4 points in the placebo group. Percentage bodyweight change was 9.8% and 3.4%, respectively (P < 0.001 for both ...

For a hierarchical composite endpoint of all-cause mortality, heart failure events, and hitting KCCQ-CSS and 6-minute walk distance thresholds, the "win" ratio was higher with semaglutide than ...

Patients with heart failure, left ventricular ejection fraction 45% or greater, body mass index ≥30 kg/m 2, and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) less ...

An analysis of a hierarchical composite endpoint (ie, death, heart failure events, change in KCCQ-CSS and 6MWD) showed that “semaglutide produced more wins than placebo” (win ratio, 1.72; 95% ...

Butler and colleagues found that, at each time point, patients on empagliflozin were more likely to improve KCCQ-CSS and less likely to experience deterioration (P for all < .05).

The mean change in KCCQ-CSS from baseline to week 52 was 16.6 points with semaglutide versus 8.7 points with placebo (estimated treatment difference [ETD]: 7.8 points, 95% confidence interval [CI ...